Yoon Sim Yap
Overview
Explore the profile of Yoon Sim Yap including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1237
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhu G, Rahman C, Getty V, Odinokov D, Baruah P, Carrie H, et al.
Nat Biomed Eng
. 2025 Mar;
PMID: 40055581
The quantification of circulating tumour DNA (ctDNA) in blood enables non-invasive surveillance of cancer progression. Here we show that a deep-learning model can accurately quantify ctDNA from the density distribution...
2.
Wan X, Yap J, Chen J, Li Y, Faruk R, Tan N, et al.
Theranostics
. 2025 Feb;
15(5):2035-2051.
PMID: 39897565
The Ser/Thr kinase RAF, particularly BRAF isoform is a dominant target of oncogenic mutations and many mutations have been identified in various cancers. However, how these mutations except V600E evade...
3.
Noguchi E, Yamanaka T, Mukai H, Yamamoto N, Chung C, Lu Y, et al.
NPJ Breast Cancer
. 2024 Aug;
10(1):76.
PMID: 39174547
Palbociclib combined with endocrine therapy is approved for treating patients with hormone-receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer; however, data on palbociclib combined with tamoxifen are limited....
4.
Lu Y, Mahidin E, Azim H, Eralp Y, Yap Y, Im S, et al.
J Clin Oncol
. 2024 May;
42(23):2812-2821.
PMID: 38771995
Purpose: A head-to-head comparison of efficacy between a cyclin-dependent kinase 4/6 inhibitor plus endocrine therapy (ET) versus combination chemotherapy (CT) has never been reported in patients with clinically aggressive hormone...
5.
Khor C, Winter S, Sutiman N, Murdter T, Chen S, Lim J, et al.
Clin Pharmacol Ther
. 2023 Jan;
113(3):712-723.
PMID: 36629403
The therapeutic efficacy of tamoxifen is predominantly mediated by its active metabolites 4-hydroxy-tamoxifen and endoxifen, whose formation is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6). Yet, known CYP2D6 polymorphisms...
6.
Poonia S, Goel A, Chawla S, Bhattacharya N, Rai P, Lee Y, et al.
Genome Res
. 2022 Nov;
33(1):80-95.
PMID: 36414416
The identification and characterization of circulating tumor cells (CTCs) are important for gaining insights into the biology of metastatic cancers, monitoring disease progression, and medical management of the disease. The...
7.
Isaac S, Pasha M, Yap Y, Chan J
Cureus
. 2022 Jul;
14(7):e26931.
PMID: 35865180
Isolated facial nerve palsy resulting from temporal bone metastasis is rare and has been sparsely reported in the literature to be the initial presentation of cancer. The most commonly reported...
8.
Loo S, Toh L, Xie W, Pathak E, Tan W, Ma S, et al.
Sci Adv
. 2021 Oct;
7(41):eabh2443.
PMID: 34613780
Cell state transitions control the functional behavior of cancer cells. Epithelial-to-mesenchymal transition (EMT) confers cancer stem cell-like properties, enhanced tumorigenicity and drug resistance to tumor cells, while mesenchymal-epithelial transition (MET)...
9.
Dai M, Feng Y, Chen S, Masuda N, Yau T, Chen S, et al.
Breast Cancer Res Treat
. 2021 Sep;
189(3):665-676.
PMID: 34553296
Purpose: Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, has demonstrated systemic efficacy and intracranial activity in various stages of HER2+breast cancer. NALA was a phase III randomized trial that assessed...
10.
Kong S, Liu X, Tan S, Tai J, Phua L, Poh H, et al.
Front Oncol
. 2021 Aug;
11:698551.
PMID: 34336686
Introduction: Circulating tumor cells (CTCs) and cell-free tumor DNA (ctDNA) are tumor components present in circulation. Due to the limited access to both CTC enrichment platforms and ctDNA sequencing in...